Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Undine Falkenhagen und 5 weiteren Autor:innen. Beteiligte Einrichtung: PharMetrX Graduate Research Training Program, Berlin/Potsdam, Germany. Hauptthemen laut MEDLINE: Warfarin, International Normalized Ratio, Anticoagulants, Cytochrome P-450 CYP2C9. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Warfarin dosing remains challenging due to substantial inter‐individual variability, which can lead to unsafe or ineffective therapy with standard dosing. Model‐informed precision dosing (MIPD) can help individualize warfarin dosing, requiring the selection of a suitable model. For models developed from clinical data, the dependence on the study design and population raises questions about generalizability. Quantitative system pharmacology (QSP) models promise better extrapolation abilities; however, their complexity and lack of validation on clinical data raise questions about applicability in MIPD. We have previously derived a mechanistic warfarin/international normalized ratio (INR) model from a blood coagulation QSP model. In this article, we evaluated the predictive performance of the warfarin/INR model in the context of MIPD using an external dataset with INR data from patients starting warfarin treatment. We assessed the accuracy and precision of model predictions, benchmarked against an empirically based reference model. Additionally, we evaluated covariate contributions and assessed the predictive performance separately in the more challenging outpatient data. The warfarin/INR model performed comparably to the reference model across various measures despite not being calibrated with warfarin initiation data. Including CYP2C9 and/or VKORC1 genotypes as covariates improved the prediction quality of the warfarin/INR model, even after assimilating 4 days of INR data. The outpatient INR exhibited higher unexplained variability, and predictions slightly exceeded observed values, suggesting that model adjustments might be necessary when transitioning from an inpatient to an outpatient setting. Overall, this research underscores the potential of QSP‐derived models for MIPD, offering a complementary approach to empirical model development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PharMetrX Graduate Research Training Program, Berlin/Potsdam, Germany.
- Institute of Mathematics, Mathematical Modelling and Systems Biology, University of Potsdam, Potsdam, Germany.
- College of Pharmacy, Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
- Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universität Berlin, Berlin, Germany.
- College of Pharmacy, Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, USA.
ORCID-Profile: Undine Falkenhagen, Larisa H Cavallari, Julio D Duarte, Charlotte Kloft, Stephan Schmidt, Wilhelm Huisinga
Zitieren
APA
Falkenhagen, U., Cavallari, L. H., Duarte, J. D., Kloft, C., Schmidt, S., & Huisinga, W. (2024). Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3274
Vancouver
Falkenhagen U, Cavallari LH, Duarte JD, Kloft C, Schmidt S, Huisinga W. Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3274
BibTeX
@article{Falkenhagen2024,
author = {Falkenhagen, Undine and Cavallari, Larisa H and Duarte, Julio D and Kloft, Charlotte and Schmidt, Stephan and Huisinga, Wilhelm},
title = {Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3274}
}
EUVIMED